Market Insight from

Penumbra’s Indigo Aspiration System expected to continue dominating US market with expanded indication

On 20 November 2020, Penumbra’s newest generation of Indigo Aspiration System, Lightning 12, received US Food and Drug Administration (FDA) clearance for the treatment of pulmonary embolism (PE).


GlobalData estimates that in 2019, almost 200,000 cases of PE occurred in the US alone, and this incidence has increased during the Covid-19 pandemic. The majority of patients receive pharmaceutical treatment for the disease; however, of the PE patients receiving endovascular treatment, over half were estimated to have undergone thrombectomy using aspiration thrombectomy systems such as the AngioJet system from Boston Scientific.


The outbreak of Covid-19 has affected many markets across medical devices. While the incidence of PE has increased during the pandemic, GlobalData has estimated that the number of endovascular procedures for clot management has experienced a low single-digit decline in the US for 2020. However, given the urgent and life-threatening nature of PEs, the impact on endovascular procedures has been minimal compared to other markets.


Penumbra reported a 43% increase in revenues in its vascular business, largely driven by the Indigo System and strong performance from the launch of its Lightning 12 system in July. The expansion of indications will likely further drive growth for Penumbra, particularly as peripheral markets continue to recover in Q4.


Penumbra’s Indigo Aspiration System is currently the market leader in the US. The approval for expanded indications allows Penumbra to enter the endovascular pulmonary embolism treatment market, where thrombectomy systems are the most frequently used, and is expected to grow steadily at a compound annual growth rate of 1% over the next ten years.


With the Indigo Aspiration System leading with the lion’s share of the thrombectomy systems market, GlobalData expects that Boston Scientific may have difficulty holding onto its market share in the coming years.


Image: Indigo System Lightning 12. Credit: Business Wire

For more insight and data, visit GlobalData's Medical Intelligence Centre

06/22/2021 18:49:21
  • Home | Becoming the first human cyborg
  • In this issue
  • Contents
  • Formacoat Company Insight
  • Formacoat
  • uvex
  • Briefing
  • Industry news
  • Covid-19 executive briefing by GlobalData
  • The medical industry briefing
  • Industrial Indexing Systems Company Insight
  • Industrial Indexing Systems
  • ElectroCraft
  • KSP
  • Electronic Sensor Technology
  • Comment
  • Robotics in medtech industry primed for significant growth to end bumpy 2020
  • AI-powered platforms expand further into traditional healthcare
  • Penumbra’s Indigo Aspiration System expected to continue dominating US market
  • Early on, 5G is already making an impact and demonstrating its potential
  • ENT market on course for full recovery following year disrupted by Covid-19
  • Research Collective Company Insight
  • Research Collective
  • Repsol
  • Sartorius
  • Peak Performance Compounding
  • In Depth
  • The ins and outs of the SABA asthma inhaler
  • Can you hear me now? The tech transforming clinical communication
  • Should biobanks release diagnostic data to patients?
  • Inside the mission to become the first cyborg
  • Miracle metal: could copper clothing help fight infection?
  • LexaGene’s new automated testing platform
  • Recurrent fainting: could a new pacemaker provide a solution?
  • Kickstarting AI and smart data in resource-limited health systems
  • BioInteractions Company Insight
  • BioInteractions
  • Sandvik Company Insight
  • Sandvik
  • ICF Mercantile
  • In Data
  • Inside the deal
  • Deals analysis
  • The medical industry key list
  • Global markets and indices
  • Macro-economic indicators
  • Macro-economic indicators (page 2)
  • Fisba
  • INDO-MIM
  • Accumold
  • GS Swiss
  • oncgnostics
  • Events
  • Next issue
  • CODIXX
  • Alicona Imaging
  • RETERO
  • Coherent
  • Eastprint Incorporated